Weekly hypofractionated radiotherapy in older adult patients with cutaneous squamous cell carcinoma

Published:September 15, 2021DOI:
      With the ageing population, the incidence rate of cutaneous squamous cell carcinoma (cSCC) increases steeply in older adult population [
      • Siegel R.L.
      • Miller K.D.
      • Jemal A.
      Cancer statistics, 2020.
      ]. This evidence poses important management challenges, due to older adult patients' clinical complexity, including comorbidities, cognitive impairment, and social issues. In this context, definitive radiotherapy (RT) represents a powerful single option in the local treatment of cSCC, although its optimal scheme remains controversial. We presented an analysis of retrospective cohort investigating the role of weekly hypofractionated RT in older adult patients with cSCC.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Geriatric Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Siegel R.L.
        • Miller K.D.
        • Jemal A.
        Cancer statistics, 2020.
        CA Cancer J. Clin. 2021; 7: 7-33
        • De Felice F.
        • Musio D.
        • Tombolini V.
        Weekly hypofractionated radiation therapy in elderly non-resectable cutaneous squamous cell carcinoma of the head and neck region.
        Radiol. Med. 2021; 126: 620-622
        • Likhacheva A.
        • Awan M.
        • Barker C.A.
        • Bhatnagar A.
        • Bradfield L.
        • Brady M.S.
        • et al.
        Definitive and postoperative radiation therapy for basal and squamous cell cancers of the skin: executive summary of an American Society for Radiation Oncology clinical practice guideline.
        Pract. Radiat. Oncol. 2020; 10: 8-20
        • de Velasco G.
        • Bex A.
        • Albiges L.
        • Powles T.
        • Rini B.I.
        • Motzer R.J.
        • et al.
        Sequencing and combination of systemic therapy in metastatic renal cell carcinoma.
        Eur. Urol. Oncol. 2019; 2: 505-514
        • Musio D.
        • De Felice F.
        • Bulzonetti N.
        • Guarnaccia R.
        • Caiazzo R.
        • Bangrazi C.
        • et al.
        Neoadjuvant-intensified treatment for rectal cancer: time to change?.
        World J. Gastroenterol. 2013; 19: 3052-3061
        • Lee Y.Y.
        • Choi M.C.
        • Park J.Y.
        • Suh D.H.
        • Kim J.W.
        Major clinical research advances in gynecologic cancer in 2020.
        J. Gynecol. Oncol. 2021; 32e53
        • Markham A.
        • Duggan S.
        First Global Approval. Drugs. 2018; 78: 1841-1846
        • European Medicines Agency (EMA)
        Libtayo (Cemiplimab).
        (Available on line:) (Accessed: June 1, 2021)